Trial · NCT00850642
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Numbers of Neutrophils in Induced Sputum-Absolute Neutrophil Count | Day -9 to -7, Day 1, Day 12 and follow-up (Day 24-28) | All Subject Population was defined as all participants who receive at least one dose of study medication. | Giga cells per g | MEAN |
| PRIMARY | Percentage of Neutrophils in Induced Sputum | Day -9 to -7, Day 1, Day 12 and follow-up (Day 24-28) | All Subject Population. Only those participants available at the specified time points were analyzed. | Percentage of neutrophils | MEAN |
| SECONDARY | Assessment of FEV1 on Visit 2, 3 and Visit 4 | Visit 2 (Day 1), visit 3 (Day 5 to 7) and visit 4 (Day 12) | All Subject population. Individual participant data reported, due to early termination of study. Data for only those participants available at the indicated time points were collected and analyzed. Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm. | Liters | NUMBER |
| SECONDARY | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | From visit 1 (Day -7 to Day -9) to upto follow-up (upto Day 28) | All Subject Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Vital Sign of Potential Clinical Concern (PCC) | Visit 2 (Day 1) to Upto follow-up (Day 28) | All subject population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Electrocardiogram (ECG) Findings | Visit 2 (Day 1) to Upto follow-up (Day 28) | All Subject Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Clinical Chemistry Values of PCC | Visit 2 (Day 1) to Upto follow-up (Day 28) | All subject population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Hematology Values of PCC | Visit 2 (Day 1) to Upto follow-up (Day 28) | All subject population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Plasma Concentration of GSK2190915 | At Day 1, pre-dose; Day 1, 2 hour; Day 12, pre-dose; and Day 12, 2 hour | All Subject Population. | Nanogram per millilitre | MEAN |
| SECONDARY | Percentage Change From Baseline Urine LTE4 Biomarker | Day 1 and Day 12 | All subject population. | Percent change | MEAN |
| SECONDARY | Percentage Change From Baseline of LTB4 Biomarker in Plasma | Day 1 and Day 12 | All subject population. | Percentage change | MEAN |
| SECONDARY | Concentration of LTB4 in Sputum | Day 1 and Day 12 | All Subject Population. Data not collected. | ||
| SECONDARY | Concentration of Interleukin (IL)-17 and High-sensitivity C-reactive Protein (hsCRP) in Blood | Day 1 and Day 12 | All Subject Population. Data not summarized for this parameter. | ||
| SECONDARY | Assessment of Established Markers of Anti-inflammatory Activity in Sputum: the Measurements Will Include IL-17, Neutrophil Elastase, Myeloperoxidase and IL-8 | Day 1 and Day 12 | All Subjects Population. Collected data were below the limit of quantification, so data could not be summarized | ||
| SECONDARY | Asthma Control Questionnaire (ACQ) Assessment | At Day 1, Day 5 to 7 and Day 12 | All Subject Population. | Scores on scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00850642/outcomes